18. Berry JD, Dyer A, Cai X, et al. Lifetime Risks of Cardiovascular Disease. N Engl J Med. 2012;366(4):321-329.
19. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. Dec 2006;26(4):847-870.
21. Cromwell WC. Clinical utilization of advanced lipid testing. In: Toth PP, Sica DA, eds. Clinical Challenges in Lipid Disorders. Oxford: Clinical Publishing; 2008:249-259.
22. Dayspring T, Helmbold A. You have a new job: monitor the lipid profile. OBG Management. 2008;20:45-53.
20. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51: 1512-1524.
23. US Department of Health and Human Services. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). Final Report. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2002. NIH Publication No. 02-5215.
24. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217S:S1-S44.
25. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non–high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98:1363-1368.
25
